Novo and returning investor Boehringer Ingelheim both contributed to the second tranche of a round that is now just over $40m in size.

Switzerland-based antibody developer NBE Therapeutics has added CHF20m from investors including pharmaceutical firms Novo and Boehringer Ingelheim to a series B round now sized at CHF40m ($40.2m).

Novo and Boehringer Ingelheim, which invested through its Boehringer Ingelheim Venture Fund (BVIF), joined PPF Capital Partners Fund, a subsidiary of investment group PPF, and unnamed private investors to supply the second tranche.

BVIF, PPF and undisclosed private investors had also provided the round’s first CHF20m in late 2016. Nanna Lüneborg, a…